Advertisement

International Journal of Clinical Oncology

, Volume 21, Issue 2, pp 231–239 | Cite as

Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer

  • Tommi T. HakalaEmail author
  • Juhani A. Sand
  • Arja Jukkola
  • Heini S. Huhtala
  • Saara Metso
  • Pirkko-Liisa Kellokumpu-Lehtinen
Original Article

Abstract

Background

The objective was to evaluate the incidence of second primary malignancies (SPMs) in thyroid cancer patients compared to age- and gender-matched controls without thyroid cancer from the general population of the same region.

Methods

Tampere and Oulu University Hospitals treated 910 patients with well-differentiated thyroid cancer during 1981–2002. The Finnish cancer registry provided follow-up data for patients and controls (n = 4542) for an average of 16 years. The incidence of invasive malignancies per 10 000 person-years was calculated and compared between patients and controls. The follow-up period ended December 31st, 2011.

Results

Young patients <40 years [Rate Ratio (RR) 1.73, p = 0.037] and patients diagnosed since 1996 (RR 1.51, p = 0.029) had an increased incidence of SPMs. Patients had an increased risk of sarcomas and soft tissue tumours (RR 4.37, p = 0.004) and haematological and lymphatic malignancies (RR 1.87, p = 0.035), especially non-Hodgkin lymphomas (RR 2.78, p = 0.035). The overall incidence of SPMs was not statistically higher in patients (109 SPMs/910 patients vs. 500 SPMs/4542 controls, RR 1.12, p = 0.269). Most patients were radioiodine-treated (81 %). The risk of SPMs with low cumulative radioiodine doses was RR 0.94 (≤3.7 GBq, p = 0.650) and with high doses RR 1.37 (>3.7 GBq, p = 0.143). Cumulative radioiodine dose increased during the study period.

Conclusions

The overall incidence of SPMs was not higher in patients than in controls. The incidence of SPMs in thyroid carcinoma patients was higher in patients <40 years old and patients diagnosed since 1996. The incidence of sarcomas and lymphomas was higher in patients than in controls.

Keywords

Thyroid cancer Second cancer Radioiodine Cancer incidence 

Notes

Acknowledgments

We would like to thank Adjunct Professor Jarkko Isotalo (University of Helsinki) and Ph.D. Maarit Leinonen (the Finnish Cancer Registry) for their contributions. This study was financially supported by Elna Kaarina Savolainen’s fund allocated for the development of cancer treatment and by the research funding of the Pirkanmaa Hospital District.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Elisei R, Molinaro E, Agate L et al (2010) Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 95:1516–1527CrossRefPubMedGoogle Scholar
  2. 2.
    Hakala T, Kellokumpu-Lehtinen P, Kholova I et al (2012) Rising incidence of small size papillary thyroid cancers with no change in disease-specific survival in Finnish thyroid cancer patients. Scand J Surg 101:301–306CrossRefPubMedGoogle Scholar
  3. 3.
    Hay ID, Gonzalez-Losada T, Reinalda MS et al (2010) Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34:1192–1202CrossRefPubMedGoogle Scholar
  4. 4.
    Engholm G, Ferlay J, Christensen N et al (2014) NORDCAN—a Nordic tool for cancer information, planning, quality control and research. Association of the Nordic Cancer Registries. Acta Oncol 49:725–736CrossRefGoogle Scholar
  5. 5.
    Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395–404CrossRefGoogle Scholar
  6. 6.
    Verburg FA, Stokkel MP, Duren C et al (2010) No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276–283CrossRefPubMedGoogle Scholar
  7. 7.
    Cooper DS, Doherty GM, Haugen BR et al (2009) Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214CrossRefPubMedGoogle Scholar
  8. 8.
    Haq M, Harmer C (2005) Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol 63:87–93CrossRefGoogle Scholar
  9. 9.
    Van Nostrand D (2009) The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 19:1381–1391CrossRefPubMedGoogle Scholar
  10. 10.
    Sandeep TC, Strachan MW, Reynolds RM et al (2006) Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825CrossRefPubMedGoogle Scholar
  11. 11.
    Brown AP, Chen J, Hitchcock YJ et al (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515CrossRefPubMedGoogle Scholar
  12. 12.
    Rubino C, De Vathaire F, Dottorini M et al (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Berthe E, Henry-Amar M, Michels J et al (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685–691CrossRefPubMedGoogle Scholar
  14. 14.
    Verkooijen RB, Smit JW, Romijn JA et al (2006) The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155:801–806CrossRefPubMedGoogle Scholar
  15. 15.
    Lu CH, Lee KD, Chen PT et al (2013) Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur J Endocrinol 169:577–585CrossRefPubMedGoogle Scholar
  16. 16.
    Iyer NG, Morris LG, Tuttle RM et al (2011) Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439–4446CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jukkola A, Bloigu R, Ebeling T et al (2004) Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 11:571–579CrossRefPubMedGoogle Scholar
  18. 18.
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin M et al (2000) International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), vol 2014. WHO, GenevaGoogle Scholar
  19. 19.
    Frome EL, Checkoway H (1985) Epidemiologic programs for computers and calculators. Use of Poisson regression models in estimating incidence rates and ratios. Am J Epidemiol 121:309–323PubMedGoogle Scholar
  20. 20.
    Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281–288CrossRefPubMedGoogle Scholar
  21. 21.
    Van Fossen VL, Wilhelm SM, Eaton JL et al (2013) Association of thyroid, breast and renal cell cancer: a population-based study of the prevalence of second malignancies. Ann Surg Oncol 20:1341–1347CrossRefPubMedGoogle Scholar
  22. 22.
    Kim C, Bi X, Pan D et al (2013) The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid 23:575–582CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pellegriti G, Frasca F, Regalbuto C et al (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:1–10CrossRefGoogle Scholar
  24. 24.
    Cramer JD, Fu P, Harth KC et al (2010) Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery 148:1147–1153CrossRefPubMedGoogle Scholar
  25. 25.
    Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167CrossRefPubMedGoogle Scholar
  26. 26.
    Blanchard CM, Denniston MM, Baker F (2003) Do adults change their lifestyle behaviors after a cancer diagnosis? Am J Health Behav 27:246–256CrossRefPubMedGoogle Scholar
  27. 27.
    de Gonzalez AB, Curtis RE, Kry SF et al (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12:353–360CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Sawka AM, Thabane L, Parlea L et al (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451–457CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2015

Authors and Affiliations

  1. 1.Department of SurgeryTampere University HospitalTampereFinland
  2. 2.School of MedicineUniversity of TampereTampereFinland
  3. 3.Division of Surgery, Gastroenterology and OncologyTampere University HospitalTampereFinland
  4. 4.Department of OncologyOulu University HospitalOuluFinland
  5. 5.School of Health SciencesUniversity of TampereTampereFinland
  6. 6.Department of EndocrinologyTampere University HospitalTampereFinland
  7. 7.Department of OncologyTampere University HospitalTampereFinland

Personalised recommendations